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Introduction: Fungal infections are an important cause of increased morbidity 
and mortality in infants admitted to neonatal intensive care units (NICUs). In 
VLBW infants, Candida (C.) albicans is the third most common cause of 
neonatal late onset sepsis (LOS). The overall incidence of candidemia in NICU 
is increasing because of the longer survival and the invasive procedures 
related with the intensive care of extremely preterm infants. Prevention of 
candidemia in neonates is supported by the identification and adequate 
management of specific risk factors, including low birth weight, use of invasive 
devices, prolonged hospitalization and use of broad-spectrum antimicrobial 
agents. Effective prophylactic strategies have recently become available, but 
the identification of the best possible strategies to manage high-risk infants is 
still a priority. Prior colonization is a key risk factor for candidemia. For this 
reason, surveillance studies to monitor incidence, species distribution, and 
antifungal susceptibility profiles are mandatory. 
 
Materials and Methods: In 2013 and 2014, we performed a cohort, prospective 
surveillance study in our NICU, collecting weekly nasal and rectal swabs. For 
each patient, clinical and demographic data expected to affect Candida 
colonization were recorded. We evaluated Candida spp. colonization rate and 
assessed the related risk factors. Swabs were placed on Sabouraud agar and 
incubated at 30°C for 4 days. Candida growth on agar was confirmed by 
microscopic observation. Moreover, Candida spp. were identified through 
Candida chromogenic agar (ChromAgar Candida, Laboratorios Conda) and 
API® 20C AUX (Biomérieux). Statistical analysis was performed by EpiInfo 
(CDC software) using the chi square or the Fisher’s exact method, when 
indicated. We assumed as statistically significant a p-value < 0.05. 
 
Results: In this 2-year study, we enrolled 520 patients and we analyzed 1,259 
nasal and 1,255 rectal swabs. From 472 out of 520 patients we collected 
complete microbiological, clinical and demographic data. 48 out of 472 
(10.17%) patients tested positive for Candida spp. at least once. In particular, 
26 patients tested positive for C. albicans, 16 for C. parapsilosis, 6 for C. 
glabrata and 1 each for C. guilliermondii and an environmental mold. All the 
colonized patients had their rectal samples positive, and 7 their nasal samples 
as well. 15 patients out of 472 (3.18%) had more than one rectal or nasal 
swab positive during their NICU stay. Importantly, 9 patients out of 15 tested 
negative at the first sampling, suggesting that they have acquired Candida 
spp. colonization during their stay. Table 1 summarizes data about risk factors 
for Candida colonization in the patients under study. No systemic infection by 
Candida spp. was reported during the study. 
 
Conclusion: Our experience suggest that an effective microbiological 
surveillance can allow for implementing proper, effective and timely control 
measures in a high-risk setting. 
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